Home › Free Stock Grades › URGN
UroGen Pharma Ltd. (URGN) Stock Grade
URGN · Healthcare
A+
Market Cap
$1.1B
P/E Ratio
—
Revenue Growth (YoY)
+21.5%
Net Margin
-139.8%
Return on Equity
145.5%
Dividend Yield
None
About UroGen Pharma Ltd.'s fundamentals
UroGen Pharma is a biotechnology company with a market capitalization of $1.1 billion that reported revenue growth of 21.5% year-over-year, indicating expanding commercial traction. However, the company operates unprofitably with a net margin of -139.8% and reported a net loss in its latest annual statement, reflecting the typical cash-burn profile of early-stage biotech firms. The company does not pay a dividend, consistent with biotech companies that prioritize reinvesting resources into research and development rather than returning capital to shareholders.